ADVERTISEMENT
Elevated GGT Prognosticates Shorter OS in Patients With Metastatic CRPC
Findings from a retrospective study suggest elevated serum γ-glutamyltransferase (GGT) as an adverse prognosticator in patients with metastatic castration-resistant prostate cancer (mCRPC) being treated with enzalutamide (Anticancer Res.2019 Oct. Epub ahead of print).
“GGT is reportedly associated with survival and therapeutic response in various malignancies; however, as far as we are aware its impact on…mCRPC…has never been assessed,” explained Kosuke Takemura, MD, PhD, Department of Urology, Tokyo Metropolitan Cancerand Infectious Diseases Center Komagome Hospital, Tokyo, Japanand colleagues.
To fill this gap in literature, Dr Takemura et al retrospectively examined a total of 50 men with mCRPC receiving enzalutamide. The primary end point of the study was overall survival (OS), and secondary end points include prostate-specific antigen (PSA) response, maximal PSA change, and PSA progression-free survival (PSA-PFS).
According to results from a multivariable analysis, shorter OS (hazard ratio [HR], 3.61; P= .004), lower hemoglobin (HR, 6.04; P<.001), and higher PSA (HR, 4.38; P= .009)were all significantly and independently tied to elevated GGT (≥40 U/l).
In addition, poorer PSA response, maximal PSA change, and shorter PSA-PFS rates were also associated with elevation of GGT.
“Elevated GGT was an adverse prognostic indicator in men with mCRPC receiving enzalutamide,” concluded Dr Takemura and colleagues.—Kaitlyn Manasterski
